Sign in or create an account to add this stock to your watchlist.
About Meridian Bioscience (NASDAQ:VIVO)
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and viral diseases, respiratory and parasitic infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the PREMIER brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand. This segment's products are primarily used in the detection of infectious diseases caused by various bacteria, viruses, parasites, and pathogens. Its products consists of C. difficile, a causative agent for antibiotic-associated diarrhea from a hospital-acquired infection; foodborne products, such as tests for Enterohemorrhagic E. coli and Campylobacter jejuni; H. pylori to detect stomach ulcers; respiratory products; and women's health and sexually transmitted diseases Group B Streptococcu, Chlamydia trachomatis, Neisseria gonorrhea, and Herpes Simplex Virus Type 1 and Type 2. This segment sells its products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells, and bioresearch reagents used by researchers, agri-bio companies, and other diagnostic manufacturing companies. The company was founded in 1976 and is headquartered in Cincinnati, Ohio.
Industry, Sector and Symbol
Industry Diagnostic substances
Sub-IndustryHealth Care Supplies
Trailing P/E Ratio22.09
Forward P/E Ratio20.85
Sales & Book Value
Annual Sales$200.77 million
Price / Sales3.12
Cash Flow$1.0625 per share
Price / Cash13.93
Book Value$4.12 per share
Price / Book3.59
EPS (Most Recent Fiscal Year)$0.67
Net Income$21.55 million
Return on Equity16.66%
Return on Assets11.38%
Meridian Bioscience (NASDAQ:VIVO) Frequently Asked Questions
What is Meridian Bioscience's stock symbol?
Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."
How often does Meridian Bioscience pay dividends? What is the dividend yield for Meridian Bioscience?
Meridian Bioscience declared a quarterly dividend on Friday, April 27th. Stockholders of record on Monday, May 7th will be paid a dividend of $0.125 per share on Thursday, May 17th. This represents a $0.50 annualized dividend and a dividend yield of 3.38%. The ex-dividend date is Friday, May 4th. View Meridian Bioscience's Dividend History.
How were Meridian Bioscience's earnings last quarter?
Meridian Bioscience, Inc. (NASDAQ:VIVO) announced its quarterly earnings data on Thursday, April, 26th. The company reported $0.21 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.21. The company had revenue of $56.45 million for the quarter, compared to analyst estimates of $55 million. Meridian Bioscience had a return on equity of 16.66% and a net margin of 8.42%. Meridian Bioscience's quarterly revenue was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.22 earnings per share. View Meridian Bioscience's Earnings History.
When is Meridian Bioscience's next earnings date?
What guidance has Meridian Bioscience issued on next quarter's earnings?
Meridian Bioscience updated its FY18 earnings guidance on Thursday, April, 26th. The company provided EPS guidance of $0.69-0.72 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.71. The company issued revenue guidance of $209-214 million, compared to the consensus revenue estimate of $210.55 million.
What price target have analysts set for VIVO?
1 brokerages have issued 12 month price objectives for Meridian Bioscience's stock. Their predictions range from $16.00 to $16.00. On average, they expect Meridian Bioscience's share price to reach $16.00 in the next year. View Analyst Ratings for Meridian Bioscience.
Who are some of Meridian Bioscience's key competitors?
Some companies that are related to Meridian Bioscience include Quidel (QDEL), Intellia Therapeutics (NTLA), New England Nuclear (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), Vermillion (VRML), Akers Biosciences (AKER), ImmuCell (ICCC), Achieve Life Sciences (ACHV), ARCA biopharma (ABIO) and GeneNews (GNWSF).
Who are Meridian Bioscience's key executives?
Meridian Bioscience's management team includes the folowing people:
- Mr. John A. Kraeutler, Exec. Chairman (Age 70)
- Ms. Melissa A. Lueke, Exec. VP, CFO, Principal Accounting Officer & Sec. (Age 55)
- Ms. Susan D. Rolih, Exec. VP of Global Regulatory & Quality Systems (Age 69)
- Mr. John P. Kenny, CEO & Director (Age 49)
- Mr. Lawrence J. Baldini, Exec. VP & Pres of Global Operations (Age 59)
Has Meridian Bioscience been receiving favorable news coverage?
News articles about VIVO stock have been trending somewhat negative on Saturday, Accern Sentiment Analysis reports. Accern scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Meridian Bioscience earned a media sentiment score of -0.15 on Accern's scale. They also assigned news headlines about the company an impact score of 47.09 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are Meridian Bioscience's major shareholders?
Meridian Bioscience's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.72%), Dimensional Fund Advisors LP (4.30%), Systematic Financial Management LP (2.40%), Millennium Management LLC (1.98%), JPMorgan Chase & Co. (1.40%) and Schwab Charles Investment Management Inc. (1.34%). Company insiders that own Meridian Bioscience stock include Dwight E Ellingwood, John A Kraeutler, John Mccune Jr Rice, John Mcilwraith, Lawrence Baldini, Melissa Lueke, Richard Eberly and Vecheslav A Elagin. View Institutional Ownership Trends for Meridian Bioscience.
Which major investors are selling Meridian Bioscience stock?
VIVO stock was sold by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Millennium Management LLC, Wells Fargo & Company MN, Spark Investment Management LLC, JPMorgan Chase & Co., Mondrian Investment Partners LTD, Russell Investments Group Ltd. and Cornercap Investment Counsel Inc.. View Insider Buying and Selling for Meridian Bioscience.
Which major investors are buying Meridian Bioscience stock?
VIVO stock was acquired by a variety of institutional investors in the last quarter, including LSV Asset Management, Systematic Financial Management LP, BlackRock Inc., Schwab Charles Investment Management Inc., GSA Capital Partners LLP, Susquehanna Fundamental Investments LLC, Hancock Holding Co. and Alambic Investment Management L.P.. Company insiders that have bought Meridian Bioscience stock in the last two years include Dwight E Ellingwood, John A Kraeutler, John Mccune Jr Rice, John Mcilwraith, Lawrence Baldini and Melissa Lueke. View Insider Buying and Selling for Meridian Bioscience.
How do I buy shares of Meridian Bioscience?
Shares of VIVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Meridian Bioscience's stock price today?
One share of VIVO stock can currently be purchased for approximately $14.80.
How big of a company is Meridian Bioscience?
Meridian Bioscience has a market capitalization of $620.34 million and generates $200.77 million in revenue each year. The company earns $21.55 million in net income (profit) each year or $0.67 on an earnings per share basis. Meridian Bioscience employs 640 workers across the globe.
How can I contact Meridian Bioscience?
Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The company can be reached via phone at 513-271-3700.
MarketBeat Community Rating for Meridian Bioscience (VIVO)MarketBeat's community ratings are surveys of what our community members think about Meridian Bioscience and other stocks. Vote "Outperform" if you believe VIVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Meridian Bioscience (NASDAQ:VIVO) Price Target and Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Meridian Bioscience in the last 12 months. Their average twelve-month price target is $16.00, suggesting that the stock has a possible upside of 8.11%. The high price target for VIVO is $16.00 and the low price target for VIVO is $16.00. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Hold||Hold||Hold|
|Consensus Rating Score: ||2.00||2.00||2.00||1.75|
|Ratings Breakdown: ||0 Sell Rating(s)|
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$16.00||$16.00||$16.00||$11.50|
|Price Target Upside: ||8.11% upside||0.00% downside||0.00% downside||23.08% downside|
Meridian Bioscience (NASDAQ:VIVO) Consensus Price Target History
Meridian Bioscience (NASDAQ:VIVO) Analyst Ratings History
(Data available from 5/26/2016 forward)
Meridian Bioscience (NASDAQ:VIVO) Dividend Information
Meridian Bioscience pays an annual dividend of $0.50 per share, with a dividend yield of 3.38%. VIVO's most recent quarterly dividend payment was Thursday, May 17. Meridian Bioscience pays out 74.63% of its earnings out as a dividend.
|Most Recent Dividend:||5/17/2018|
|Payout Ratio(s):||74.63% (Trailing 12 Months of Earnings) |
70.42% (Based on This Year's Estimates)
64.94% (Based on Next Year's Estimates)
47.06% (Based on Cash Flow)
Meridian Bioscience (NASDAQ:VIVO) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Meridian Bioscience (NASDAQ VIVO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 2.70%
Institutional Ownership Percentage: 86.97%
Meridian Bioscience (NASDAQ VIVO) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|2/23/2018||John Mcilwraith||Director||Buy||1,000||$14.03||$14,030.00||4,000|| |
|2/7/2018||John Mccune Jr. Rice||Director||Buy||1,000||$14.75||$14,750.00|| |
|8/24/2017||John A Kraeutler||Chairman||Buy||7,000||$13.67||$95,690.00||345,230|| |
|2/2/2017||Melissa Lueke||CFO||Buy||4,000||$12.59||$50,360.00||167,071|| |
|1/26/2017||Lawrence Baldini||EVP||Buy||4,000||$12.70||$50,800.00||106,934|| |
|12/2/2016||Vecheslav A Elagin||EVP||Sell||7,883||$17.30||$136,375.90||52,926|| |
|11/30/2016||Dwight E Ellingwood||Director||Buy||1,020||$17.12||$17,462.40||7,000|| |
|11/16/2016||Richard Eberly||EVP||Sell||4,926||$17.00||$83,742.00||48,719|| |
|11/4/2016||John A Kraeutler||Chairman||Buy||5,000||$16.13||$80,650.00||316,683|| |
|11/3/2016||Lawrence Baldini||EVP||Buy||4,900||$16.00||$78,400.00||95,501|| |
|8/11/2016||John Mcilwraith||Director||Buy||1,000||$19.57||$19,570.00||3,000|| |
|4/29/2016||Catherine Sazdanoff||Director||Buy||7,700||$19.20||$147,840.00||7,700|| |
|12/9/2015||Vecheslav A Elagin||EVP||Sell||7,500||$19.75||$148,125.00||54,459|| |
|12/1/2015||Richard Eberly||EVP||Sell||4,934||$19.61||$96,755.74||46,219|| |
|3/2/2015||Marviette D Johnson||VP||Sell||1,917||$19.91||$38,167.47|| |
|1/23/2015||Dwight E Ellingwood||Director||Buy||1,980||$17.74||$35,125.20|| |
|12/1/2014||Susan Rolih||EVP||Sell||11,219||$16.46||$184,664.74|| |
|11/21/2014||Dwight E Ellingwood||Director||Buy||1,000||$16.08||$16,080.00|| |
|11/18/2014||John A Kraeutler||CEO||Sell||10,500||$16.20||$170,100.00|| |
|11/18/2014||Melissa Lueke||CFO||Sell||6,713||$16.20||$108,750.60|| |
|11/11/2014||David Phillips||Director||Buy||10,000||$16.89||$168,900.00|| |
|6/13/2014||Robert J Ready||Director||Sell||2,700||$20.03||$54,081.00|| |
|12/5/2013||Vecheslav Elagin||EVP||Sell||4,141||$23.74||$98,307.34||50,500|| |
|11/22/2013||Susan Rolih||EVP||Sell||9,086||$24.18||$219,699.48||106,702|| |
|11/21/2013||Richard Eberly||EVP||Sell||4,926||$24.50||$120,687.00||40,755|| |
|11/19/2013||Lawrence Baldini||VP||Sell||4,926||$24.26||$119,504.76||75,500|| |
|11/11/2013||John Kraeutler||CEO||Sell||5,250||$25.27||$132,667.50||270,718|| |
|7/26/2013||Lawrence Baldini||VP||Sell||32,000||$24.14||$772,480.00|| |
|5/1/2013||John A Kraeutler||CEO||Buy||5,000||$19.63||$98,150.00|| |
|12/3/2012||Lawrence Baldini||VP||Sell||32,500||$20.00||$650,000.00|| |
|11/13/2012||Robert J Ready||Director||Sell||1,800||$19.46||$35,028.00|| |
Meridian Bioscience (NASDAQ VIVO) News Headlines
|$0.17 EPS Expected for Meridian Bioscience, Inc. (VIVO) This Quarter|
www.americanbankingnews.com - May 25 at 12:38 PM
|Meridian Bioscience (VIVO) Presents At 2018 UBS Global Healthcare Conference - Slideshow|
seekingalpha.com - May 22 at 5:18 PM
|Meridian Bioscience (VIVO) versus Vermillion (VRML) Head-To-Head Survey|
www.americanbankingnews.com - May 20 at 5:25 AM
|Critical Survey: Meridian Bioscience (VIVO) & Immunomedics (IMMU)|
www.americanbankingnews.com - May 12 at 3:21 AM
|$51.96 Million in Sales Expected for Meridian Bioscience (VIVO) This Quarter|
www.americanbankingnews.com - May 10 at 5:13 AM
|Meridian Bioscience (VIVO) Expected to Post Earnings of $0.17 Per Share|
www.americanbankingnews.com - May 8 at 1:14 AM
|Meridian Bioscience (VIVO) Upgraded at Zacks Investment Research|
www.americanbankingnews.com - May 1 at 3:10 PM
|Is Buying Meridian Bioscience Inc (NASDAQ:VIVO) For Its Upcoming $0.13 Dividend A Good Choice?|
finance.yahoo.com - April 30 at 5:26 PM
|Comparing New England Nuclear (LNTH) and Meridian Bioscience (VIVO)|
www.americanbankingnews.com - April 30 at 3:20 PM
|Q4 2018 EPS Estimates for Meridian Bioscience Increased by Piper Jaffray (VIVO)|
www.americanbankingnews.com - April 30 at 4:01 AM
|FY2018 EPS Estimates for Meridian Bioscience (VIVO) Lifted by Analyst|
www.americanbankingnews.com - April 30 at 3:26 AM
|Meridian Bioscience (VIVO) to Issue Quarterly Dividend of $0.13|
www.americanbankingnews.com - April 27 at 6:00 PM
|Meridian Bioscience: Fiscal 2Q Earnings Snapshot|
finance.yahoo.com - April 26 at 5:28 PM
|Meridian Bioscience (VIVO) Posts Quarterly Earnings Results, Meets Estimates|
www.americanbankingnews.com - April 26 at 2:18 PM
|Meridian Bioscience (VIVO) Issues FY18 Earnings Guidance|
www.americanbankingnews.com - April 26 at 9:26 AM
|Meridian Bioscience Reports Second Quarter 2018 Operating Results, Declares Regular Second Quarter Cash Dividend, and Updates Fiscal 2018 Guidance|
finance.yahoo.com - April 26 at 8:02 AM
|Comparing Quotient (QTNT) and Meridian Bioscience (VIVO)|
www.americanbankingnews.com - April 25 at 11:16 PM
|$54.39 Million in Sales Expected for Meridian Bioscience, Inc. (VIVO) This Quarter|
www.americanbankingnews.com - April 22 at 1:02 AM
|Zacks: Brokerages Expect Meridian Bioscience, Inc. (VIVO) to Announce $0.20 EPS|
www.americanbankingnews.com - April 20 at 11:14 PM
|Meridian Bioscience (VIVO) to Release Quarterly Earnings on Thursday|
www.americanbankingnews.com - April 19 at 3:16 AM
|Meridian Bioscience (VIVO) Stock Rating Lowered by Zacks Investment Research|
www.americanbankingnews.com - April 13 at 1:35 PM
|Zacks: Analysts Anticipate Meridian Bioscience, Inc. (VIVO) Will Post Quarterly Sales of $54.00 Million|
www.americanbankingnews.com - April 6 at 5:16 AM
|Meridian Bioscience (VIVO) Cut to "Sell" at Zacks Investment Research|
www.americanbankingnews.com - April 5 at 9:00 PM
| Brokerages Expect Meridian Bioscience, Inc. (VIVO) Will Post Earnings of $0.20 Per Share|
www.americanbankingnews.com - April 4 at 1:22 AM
|Zacks Investment Research Downgrades Meridian Bioscience (VIVO) to Hold|
www.americanbankingnews.com - March 29 at 3:00 PM
|Meridian Bioscience (VIVO) Realigns Organizational Structure|
www.streetinsider.com - March 21 at 5:53 PM
|Meridian Bioscience (VIVO) Raised to Buy at Zacks Investment Research|
www.americanbankingnews.com - March 21 at 2:13 PM
|Meridian Bioscience Realigns Business Structure - Quick Facts|
www.rttnews.com - March 21 at 8:16 AM
|Meridian Bioscience Realigns Organizational Structure|
finance.yahoo.com - March 21 at 8:16 AM
| Brokerages Anticipate Meridian Bioscience, Inc. (VIVO) Will Announce Quarterly Sales of $53.35 Million|
www.americanbankingnews.com - March 19 at 2:26 AM
|Meridian Bioscience, Inc. (VIVO) Expected to Post Earnings of $0.20 Per Share|
www.americanbankingnews.com - March 17 at 11:14 PM
|Meridian Bioscience (VIVO) Raised to "Hold" at BidaskClub|
www.americanbankingnews.com - March 10 at 10:28 PM
|Connors Investor Services Inc. Decreases Stake in Meridian Bioscience, Inc. (VIVO)|
www.americanbankingnews.com - March 5 at 1:54 PM
|Meridian Bioscience, Inc. (VIVO) Position Lifted by Martingale Asset Management L P|
www.americanbankingnews.com - March 3 at 11:50 AM
|Zacks: Analysts Anticipate Meridian Bioscience, Inc. (VIVO) Will Announce Quarterly Sales of $53.35 Million|
www.americanbankingnews.com - March 2 at 2:28 AM
|Spark Investment Management LLC Has $2.89 Million Stake in Meridian Bioscience, Inc. (VIVO)|
www.americanbankingnews.com - February 28 at 5:44 PM
|American Century Companies Inc. Purchases Shares of 137,306 Meridian Bioscience, Inc. (VIVO)|
www.americanbankingnews.com - February 27 at 4:06 AM
|Insider Buying: Meridian Bioscience, Inc. (VIVO) Director Buys 1,000 Shares of Stock|
www.americanbankingnews.com - February 26 at 12:16 PM
|Contrasting Meridian Bioscience (VIVO) and Lombard Medical (EVARF)|
www.americanbankingnews.com - February 18 at 7:02 PM
|Meridian Bioscience, Inc. (VIVO) Expected to Announce Quarterly Sales of $53.35 Million|
www.americanbankingnews.com - February 14 at 12:46 PM
|Lawsuit for Investors in Meridian Bioscience, Inc. (NASDAQ: VIVO) Shares Announced by Shareholders Foundation|
finance.yahoo.com - February 12 at 3:33 PM
| Brokerages Anticipate Meridian Bioscience, Inc. (VIVO) to Announce $0.20 EPS|
www.americanbankingnews.com - February 12 at 5:12 AM
|Meridian Bioscience, Inc. (VIVO) Director John Mccune Jr. Rice Acquires 1,000 Shares|
www.americanbankingnews.com - February 8 at 4:20 AM
|Active-Investors: Free Post Earnings Research Report: Meridian's Quarterly Revenue Grew 12%; Non-GAAP Earnings Advanced 4%|
www.finanznachrichten.de - February 5 at 8:00 AM
|Free Post Earnings Research Report: Meridian’s Quarterly Revenue Grew 12%; Non-GAAP Earnings Advanced 4%|
finance.yahoo.com - February 5 at 8:00 AM
|Meridian Bioscience (VIVO) Downgraded to Sell at BidaskClub|
www.americanbankingnews.com - February 3 at 1:38 PM
|William Blair Comments on Meridian Bioscience, Inc.'s FY2019 Earnings (VIVO)|
www.americanbankingnews.com - January 29 at 7:46 AM
|Meridian Bioscience, Inc. (VIVO) Declares Quarterly Dividend of $0.13|
www.americanbankingnews.com - January 28 at 7:31 AM
| Brokerages Anticipate Meridian Bioscience, Inc. (VIVO) Will Announce Quarterly Sales of $53.26 Million|
www.americanbankingnews.com - January 28 at 5:48 AM
|Meridian Bioscience (VIVO) Price Target Increased to $16.00 by Analysts at Canaccord Genuity|
www.americanbankingnews.com - January 26 at 3:18 PM
Meridian Bioscience (NASDAQ:VIVO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Meridian Bioscience (NASDAQ:VIVO) Income Statement, Balance Sheet and Cash Flow Statement
Meridian Bioscience (NASDAQ VIVO) Stock Chart for Saturday, May, 26, 2018